Tagrisso (Osimertinib)

Brand Options

arrow pointer

Brand Name : Tagrisso

Marketing Authorization Holder : AstraZeneca

Prescription Required

 
 
No Generic Medicine available for this medicine.

Product Details

Tagrisso

Save over 50% on Tagrisso brand medicine by Astra Zeneca.

English and Non-english packaging - English label and English insert included.

Manufacturer for all European Tagrisso: AstraZeneca AB Gärtunavägen SE-152 57 Södertälje Sweden

Information about Tagrisso (Osimertinib)

Tagrisso (generic name: Osimertinib) is a prescription medication used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It is categorized as a tyrosine kinase inhibitor (TKI). Osimertinib targets and blocks the epidermal growth factor receptor (EGFR) mutations, including the T790M mutation, which contributes to cancer cell growth in NSCLC. Tagrisso is often used after other EGFR-targeted therapies have failed, particularly in cases of acquired resistance due to the T790M mutation.

Product Highlights

  • Tagrisso is primarily used to treat advanced or metastatic NSCLC in patients who have an EGFR mutation, particularly the T790M mutation, after disease progression on other EGFR inhibitors.
  • It is also approved as a first-line treatment for patients with metastatic NSCLC with EGFR mutations, providing an alternative to chemotherapy and other treatments.

Key Ingredient:

  • Osimertinib

Key Benefits

  • Tagrisso specifically targets and blocks EGFR mutations, including the T790M mutation, thereby inhibiting cancer cell growth and spread. 
  • In clinical trials, Osimertinib has been shown to improve progression-free survival in patients with EGFR-mutant NSCLC, particularly those with the T790M resistance mutation.
  • Tagrisso is often better tolerated than traditional chemotherapy and other EGFR inhibitors, with fewer severe side effects.
  • It is especially beneficial for patients who have developed resistance to other EGFR-targeted therapies, offering a treatment option when other medications no longer work.

Direction of Use

  • The usual starting dose of Tagrisso is 80 mg once a day, with or without food. The dose may be adjusted depending on side effects and the patient's overall response to the medication.
  • The tablets should be swallowed whole and not broken or chewed. If a dose is missed, it should be taken as soon as possible, unless it is close to the time of the next dose.
  • Tagrisso is typically continued until the disease progresses or intolerable side effects develop. 

Safety Concerns

  • Common side effects include diarrhea, skin rashes, dry skin, mouth sores, fatigue, and decreased appetite.
  • Serious side effects can include interstitial lung disease (ILD), heart problems (e.g., QT interval prolongation), and severe skin reactions. Liver function should be monitored, as the medication may impact liver enzymes. 
  • Regular monitoring of heart function (e.g., ECG) and lung function (for ILD) is recommended during treatment. Liver function tests should also be conducted to ensure the drug is not adversely affecting liver health.

Avoid Tagrisso (Osimertinib) If

  • Do not use Tagrisso if you are allergic to osimertinib or any of its ingredients. 
  • If you have a history of interstitial lung disease (ILD) or other severe lung conditions, consult with your doctor before starting treatment.
  • Avoid Tagrisso if you have heart conditions that involve QT prolongation or irregular heartbeats, as it may exacerbate these issues.
  • People with severe liver impairment may need adjustments to their dose or should avoid this medication if their condition cannot be managed properly.


Image Image Image Image